Need help finding what you are looking for?
Contact Us
PUBLISHER: The Business Research Company | PRODUCT CODE: 1657248
PUBLISHER: The Business Research Company | PRODUCT CODE: 1657248
Coronavirus (COVID-19) Current Therapy Global Market Opportunities And Strategies To 2034
PUBLISHED:
PAGES: 302 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
coronavirus (COVID-19) current therapy refers to the range of pharmaceutical treatments and therapeutic interventions used to manage and treat the symptoms of COVID-19, reduce viral load and prevent severe outcomes such as hospitalization or death. These therapies target the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) virus, associated inflammation and complications caused by the disease, aiming to improve recovery rates and minimize long-term health impacts.
The coronavirus (COVID-19) current therapy market consists of sales, by entities (organizations, sole traders, or partnerships), of coronavirus (COVID-19) current therapy that are utilized by a wide demographic of patients diagnosed with the virus, encompassing mild, moderate and severe cases. These treatments are employed in both acute and long-term care scenarios, ranging from early-stage intervention to advanced care for critically ill patients. The therapies are often used in combination with supportive measures such as oxygen therapy, mechanical ventilation and other critical care practices, complementing the mainstay antiviral and anti-inflammatory drugs.
The global coronavirus (COVID-19) current therapy market declined to $9,367.71 million in 2024.
Expanding Clinical Trials
During the historic period, the expanding clinical trials supported the growth of coronavirus (COVID-19) current therapy market. Clinical trials play a crucial role in systematically evaluating the safety and efficacy of emerging treatments, which builds trust among healthcare providers and patients. Positive outcomes from these trials support regulatory approvals, facilitating the widespread adoption of new therapies. Results from clinical trials, particularly Phase II and Phase III studies, provide the necessary data for regulatory bodies to expedite approval processes. These accelerated approvals have contributed to the swift introduction of new therapies, enhancing the landscape of COVID-19 treatments. For instance, in November 2023, according to a report published by the Association of the British Pharmaceutical Industry (ABPI), a UK-based association, there were 394 trials in 2021; the clinical trial number increased to 411 in 2022. Additionally, in May 2023, according to Xtalks, a Canada-based company specializing in providing life science webinars and virtual events, there are 452,604 clinical studies that have been registered on ClinicalTrials.gov as of May 17, 2023. 64,838 studies out of the total number that have been registered are actively seeking participants which is an increase of 365,000 registered trials in 2021. Therefore, the expanding clinical trials drove the growth of coronavirus (COVID-19) current therapy market.
Advancements In Antiviral Drug Development For COVID-19 Treatment
Companies operating in the coronavirus (COVID-19) current therapy market are focusing on developing antiviral drugs to address the evolving needs of patients and enhance therapeutic outcomes. Antiviral drugs are specialized treatments developed to combat viral infections by disrupting the replication and spread of viruses within the body. Antiviral drugs are uniquely tailored to target viruses. For instance, in May 2023, Pfizer Inc., a US-based pharmaceutical company received approval from the U.S. Food and Drug Administration (FDA) for the oral antiviral treatment, PAXLOVID. This drug is used for the treatment of adults with mild-to-moderate COVID-19 who are at high risk of severe outcomes, including hospitalization or death. Clinical studies have shown that PAXLOVID significantly reduces the risk of hospitalization or death by approximately 86% when administered within five days of symptom onset.
The global coronavirus (COVID-19) current therapy market is concentrated, with large players operating in the market. The top ten competitors in the market made up to 40.4% of the total market in 2023.
Coronavirus (COVID-19) Current Therapy Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global coronavirus (COVID-19) current therapy market as it emerges from the COVID-19 shut down.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Where is the largest and fastest-growing market for coronavirus (COVID-19) current therapy? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The coronavirus (COVID-19) current therapy market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider coronavirus (COVID-19) current therapy market; and compares it with other markets.
The report covers the following chapters
- Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by drug type, by route of administration and by end-user.
- Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Macro-Economic Scenario- The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the COVID-19 current therapy market.
- Global Market Size And Growth- Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional And Country Analysis- Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
- Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by drug type, by route of administration and by end-user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
- Regional Market Size and Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major And Innovative Companies- Details on the company profiles of other major and innovative companies in the market.
- Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
- Competitive Dashboard- Briefs on competitive dashboard of major players.
- Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
- Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions And Recommendations- This section includes recommendations for coronavirus (COVID-19) current therapy providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
- 1) By Drug Type: Antivirals; Monoclonal Antibodies (Mabs); Corticosteroid; Supplements; Antimalarial; Interferons And Interleukin Inhibitors; Other Anti Infections; Others
- 2) By Route Of Administration: Oral; Intravenous
- 3) By End User: Hospitals; Clinics; Home Care; Other End Users
- Companies Mentioned: Gilead Sciences, Inc.; Merck & Co; Regeneron Pharmaceuticals, Inc; F. Hoffmann-La Roche AG; Ipca Laboratories Limited
- Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time-series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; coronavirus (COVID-19) current therapy indicators comparison.
- Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Product Code: o&s1493
Table of Contents
1 Executive Summary
- 1.1 Coronavirus (COVID-19) Current Therapy - Market Attractiveness And Macro economic Landscape
2 Table Of Contents
3 List Of Tables
4 List Of Figures
5 Report Structure
6 Market Characteristics
- 6.1 General Market Definition
- 6.2 Summary
- 6.3 Coronavirus (COVID-19) Current Therapy Market Definition And Segmentations
- 6.4 Market Segmentation By Drug Type
- 6.4.1 Antivirals
- 6.4.2 Monoclonal Antibodies (Mabs)
- 6.4.3 Corticosteroid
- 6.4.4 Supplements
- 6.4.5 Antimalarial
- 6.4.6 Interferons And Interleukin Inhibitors
- 6.4.7 Other Anti Infections
- 5.4.8 Others
- 6.5 Market Segmentation By Route Of Administration
- 6.5.1 Oral
- 6.5.2 Intravenous
- 6.6 Market Segmentation By End-User
- 6.6.1 Hospitals
- 6.6.2 Clinics
- 6.6.3 Home Care
- 6.6.4 Other End-Users
7 Major Market Trends
- 7.1 Strategic Investments Driving COVID-19 Therapy Market Growth
- 7.2 Advancements In Antiviral Drug Development For COVID-19 Treatment
- 7.3 Digital Solutions Transforming Healthcare Accessibility
8 Coronavirus (COVID-19) Current Therapy Market - Macro Economic Scenario
- 8.1 COVID-19 Impact On The Coronavirus (COVID-19) Current Therapy Market
- 8.2 Impact Of The War In Ukraine On The Coronavirus (COVID-19) Current Therapy Market
- 8.3 Impact Of High Inflation On The Coronavirus (COVID-19) Current Therapy Market
9 Global Market Size and Growth
- 9.1 Market Size
- 9.2 Historic Market Growth, 2019 - 2024, Value ($ Million)
- 9.2.1 Market Drivers 2019 - 2024
- 9.2.2 Market Restraints 2019- 2024
- 9.3 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
- 9.3.1 Market Drivers 2024 - 2029
- 9.3.2 Market Restraints 2024 - 2029
10 Global Coronavirus (COVID-19) Current Therapy Market Segmentation
- 10.1 Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 10.2 Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 10.3 Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11 Coronavirus (COVID-19) Current Therapy Market, Regional and Country Analysis
- 11.1 Global Coronavirus (COVID-19) Current Therapy Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 11.2 Global Coronavirus (COVID-19) Current Therapy Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12 Asia-Pacific Market
- 12.1 Summary
- 12.1.1 Market Overview
- 12.1.2 Region Information
- 12.1.3 Market Information
- 12.1.4 Background Information
- 12.1.5 Government Initiatives
- 12.1.6 Regulations
- 12.1.7 Regulatory Bodies
- 12.1.8 Major Associations
- 12.1.9 Taxes Levied
- 12.1.10 Corporate Tax Structure
- 12.1.11 Investments
- 12.1.12 Major Companies
- 12.2 Asia-Pacific Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 12.3 Asia-Pacific Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 12.4 Asia-Pacific Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 12.5 Asia-Pacific Coronavirus (COVID-19) Current Therapy Market: Country Analysis
- 12.6 China Market
- 12.7 Summary
- 12.7.1 Market Overview
- 12.7.2 Country Information
- 12.7.3 Market Information
- 12.7.4 Background Information
- 12.7.5 Government Initiatives
- 12.7.6 Regulations
- 12.7.7 Regulatory Bodies
- 12.7.8 Major Associations
- 12.7.9 Taxes Levied
- 12.7.10 Corporate Tax Structure
- 12.7.11 Investments
- 12.7.12 Major Companies
- 12.8 China Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 12.9 China Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 12.10 China Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 12.11 India Market
- 12.12 India Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 12.13 India Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 12.14 India Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 12.15 Japan Market
- 12.16 Japan Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 12.17 Japan Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 12.18 Japan Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 12.19 Australia Market
- 12.20 Australia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 12.21 Australia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 12.22 Australia Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 12.23 Indonesia Market
- 12.24 Indonesia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 12.25 Indonesia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 12.26 Indonesia Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 12.27 South Korea Market
- 12.28 South Korea Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 12.29 South Korea Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 12.30 South Korea Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13 Western Europe Market
- 13.1 Summary
- 13.1.1 Market Overview
- 13.1.2 Region Information
- 13.1.3 Market Information
- 13.1.4 Background Information
- 13.1.5 Government Initiatives
- 13.1.6 Regulations
- 13.1.7 Regulatory Bodies
- 13.1.8 Major Associations
- 13.1.9 Taxes Levied
- 13.1.10 Corporate Tax Structure
- 13.1.11 Investments
- 13.1.12 Major Companies
- 13.2 Western Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 13.3 Western Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 13.4 Western Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 13.5 UK Market
- 13.6 UK Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 13.7 UK Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 13.8 UK Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 13.9 Germany Market
- 13.10 Germany Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 13.11 Germany Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 13.12 Germany Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 13.13 France Market
- 13.14 France Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 13.15 France Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 13.16 France Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 13.17 Italy Market
- 13.18 Italy Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 13.19 Italy Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 13.20 Italy Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 13.21 Spain Market
- 13.22 Spain Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 13.23 Spain Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 13.24 Spain Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14 Eastern Europe Market
- 14.1 Summary
- 14.1.1 Market Overview
- 14.1.2 Region Information
- 14.1.3 Market Information
- 14.1.4 Background Information
- 14.1.5 Government Initiatives
- 14.1.6 Regulations
- 14.1.7 Regulatory Bodies
- 14.1.8 Major Associations
- 14.1.9 Taxes Levied
- 14.1.10 Corporate Tax Structure
- 14.1.11 Investments
- 14.1.12 Major Companies
- 14.2 Eastern Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 14.3 Eastern Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 14.4 Eastern Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 14.5 Russia Market
- 14.6 Russia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 14.7 Russia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 14.8 Russia Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15 North America Market
- 15.1 Summary
- 15.1.1 Market Overview
- 15.1.2 Region Information
- 15.1.3 Market Information
- 15.1.4 Background Information
- 15.1.5 Government Initiatives
- 15.1.6 Regulations
- 15.1.7 Regulatory Bodies
- 15.1.8 Major Associations
- 15.1.9 Taxes Levied
- 15.1.10 Corporate Tax Structure
- 15.1.11 Investments
- 15.1.12 Major Companies
- 15.2 North America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 15.3 North America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 15.4 North America Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 15.5 North America Coronavirus (COVID-19) Current Therapy Market: Country Analysis
- 15.6 USA Market
- 15.7 Summary
- 15.7.1 Market Overview
- 15.7.2 Country Information
- 15.7.3 Market Information
- 15.7.4 Background Information
- 15.7.5 Government Initiatives
- 15.7.6 Regulations
- 15.7.7 Regulatory Bodies
- 15.7.8 Major Associations
- 15.7.9 Taxes Levied
- 15.7.10 Corporate Tax Structure
- 15.7.11 Investments
- 15.7.12 Major Companies
- 15.8 USA Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 15.9 USA Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 15.10 USA Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 15.11 Canada Market
- 15.12 Canada Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 15.13 Canada Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 15.14 Canada Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16 South America Market
- 16.1 Summary
- 16.1.1 Market Overview
- 16.1.2 Region Information
- 16.1.3 Market Information
- 16.1.4 Background Information
- 16.1.5 Government Initiatives
- 16.1.6 Regulations
- 16.1.7 Regulatory Bodies
- 16.1.8 Major Associations
- 16.1.9 Taxes Levied
- 16.1.10 Corporate Tax Structure
- 16.1.11 Investments
- 16.1.12 Major Companies
- 16.2 South America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 16.3 South America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 16.4 South America Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
17 Middle East Market
- 17.1 Summary
- 17.1.1 Market Overview
- 17.1.2 Region Information
- 17.1.3 Market Information
- 17.1.4 Background Information
- 17.1.5 Government Initiatives
- 17.1.6 Regulations
- 17.1.7 Regulatory Bodies
- 17.1.8 Major Associations
- 17.1.9 Taxes Levied
- 17.1.10 Corporate Tax Structure
- 17.1.11 Investments
- 17.1.12 Major Companies
- 17.2 Middle East Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 17.3 Middle East Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 17.4 Middle East Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
18 Africa Market
- 18.1 Summary
- 18.1.1 Market Overview
- 18.1.2 Region Information
- 18.1.3 Market Information
- 18.1.4 Background Information
- 18.1.5 Government Initiatives
- 18.1.6 Regulations
- 18.1.7 Regulatory Bodies
- 18.1.8 Major Associations
- 18.1.9 Taxes Levied
- 18.1.10 Corporate Tax Structure
- 18.1.11 Major Companies
- 18.2 Africa Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 18.3 Africa Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
- 18.4 Africa Coronavirus (COVID-19) Current Therapy Market, Segmentation By End-User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
19 Competitive Landscape And Company Profiles
- 19.1 Company Profiles
- 19.2 Gilead Sciences, Inc
- 19.2.1 Company Overview
- 19.2.2 Products And Services
- 19.2.3 Financial Overview
- 19.3 Merck & Co., Inc.
- 19.3.1 Company Overview
- 19.3.2 Products And Services
- 19.3.3 Business Strategy
- 19.3.4 Financial Overview
- 19.4 Regeneron Pharmaceuticals Inc
- 19.4.1 Company Overview
- 19.4.2 Products And Services
- 19.4.3 Business Strategy
- 19.4.4 Financial Overview
- 19.5 F. Hoffman-La Roche Ltd
- 19.5.1 Company Overview
- 19.5.2 Products And Services
- 19.5.3 Business Strategy
- 19.5.4 Financial Overview
- 19.6 Ipca Laboratories Limited
- 19.6.1 Company Overview
- 19.6.2 Products And Services
- 19.6.3 Financial Overview
20 Other Major And Innovative Companies
- 20.1 Zydus Group
- 20.1.1 Company Overview
- 20.1.2 Products and Services
- 20.2 Sun Pharmaceutical Industries Limited
- 20.2.1 Company Overview
- 20.2.2 Products and Services
- 20.3 AbbVie Inc
- 20.3.1 Company Overview
- 20.3.2 Products and Services
- 20.4 Pfizer Inc
- 20.4.1 Company Overview
- 20.4.2 Products and Services
- 20.5 Glenmark Pharmaceuticals Limited
- 20.5.1 Company Overview
- 20.5.2 Products and Services
- 20.6 Eli Lilly and Company
- 20.6.1 Company Overview
- 20.6.2 Products and Services
- 20.7 Sanofi SA
- 20.7.1 Company Overview
- 20.7.2 Products and Services
- 20.8 GSK (GlaxoSmithKline)
- 20.8.1 Company Overview
- 20.8.2 Products and Services
- 20.9 Novavax Inc
- 20.9.1 Company Overview
- 20.9.2 Products and Services
- 20.10 AstraZeneca
- 20.10.1 Company Overview
- 20.10.2 Products and Services
- 20.11 Johnson & Johnson
- 20.11.1 Company Overview
- 20.11.2 Products and Services
- 20.12 Moderna Inc
- 20.12.1 Company Overview
- 20.12.2 Products and Services
- 20.13 CureVac N.V.
- 20.13.1 Company Overview
- 20.13.2 Products and Services
- 20.14 Wallace Pharmaceuticals, Inc
- 20.14.1 Company Overview
- 20.14.2 Products and Services
- 20.15 Clover Biopharmaceuticals Ltd
- 20.15.1 Company Overview
- 20.15.2 Products and Services
21 Competitive Benchmarking
22 Competitive Dashboard
23 Key Mergers And Acquisitions
- 23.1 GSK Acquires CureVac
- 23.2 FSII-Pardes Biosciences Merger Aims To Enhance COVID-19 Antiviral Therapy Capabilities
24 Opportunities And Strategies
- 24.1 Global Coronavirus (COVID-19) Current Therapy Market In 2029 - Growth Strategies
- 24.1.1 Market Trend Based Strategies
- 24.1.2 Competitor Strategies
25 COVID-19 Current Therapy Market, Conclusions And Recommendations
- 25.1 Conclusions
- 25.2 Recommendations
- 25.2.1 Product
- 25.2.2 Place
- 25.2.3 Price
- 25.2.4 Promotion
- 25.2.5 People
26 Appendix
- 26.1 Geographies Covered
- 26.2 Market Data Sources
- 26.3 Research Methodology
- 26.4 Currencies
- 26.5 The Business Research Company
- 26.6 Copyright and Disclaimer
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.